| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymerase Chain Reaction | 22 | 2020 | 922 | 2.710 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 124 | 1.470 |
Why?
|
| DNA, Bacterial | 5 | 2020 | 244 | 1.320 |
Why?
|
| Pathology | 3 | 2018 | 32 | 1.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 6 | 2019 | 282 | 1.050 |
Why?
|
| Pancreatic Neoplasms | 8 | 2024 | 687 | 1.040 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 1201 | 1.000 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2024 | 83 | 0.980 |
Why?
|
| Curriculum | 4 | 2022 | 568 | 0.930 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 48 | 0.890 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 34 | 0.870 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2024 | 487 | 0.850 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2010 | 106 | 0.820 |
Why?
|
| Pathologists | 1 | 2022 | 27 | 0.810 |
Why?
|
| Prostatic Neoplasms | 9 | 2015 | 1781 | 0.730 |
Why?
|
| Mutation | 6 | 2024 | 4166 | 0.720 |
Why?
|
| Laboratories, Hospital | 1 | 2020 | 8 | 0.720 |
Why?
|
| Tuberculosis | 2 | 2020 | 121 | 0.670 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2014 | 75 | 0.640 |
Why?
|
| beta-Lactamases | 3 | 2013 | 56 | 0.610 |
Why?
|
| Staphylococcal Infections | 7 | 2013 | 271 | 0.600 |
Why?
|
| Pandemics | 2 | 2020 | 776 | 0.570 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2019 | 73 | 0.570 |
Why?
|
| Humans | 82 | 2024 | 89685 | 0.560 |
Why?
|
| Precision Medicine | 2 | 2020 | 413 | 0.550 |
Why?
|
| Bacterial Typing Techniques | 2 | 2007 | 28 | 0.550 |
Why?
|
| Influenza, Human | 4 | 2019 | 339 | 0.530 |
Why?
|
| Transforming Growth Factor beta | 3 | 2020 | 324 | 0.520 |
Why?
|
| Prostatectomy | 3 | 2013 | 478 | 0.490 |
Why?
|
| DNA Primers | 6 | 2011 | 544 | 0.480 |
Why?
|
| Bone Marrow Cells | 2 | 2006 | 262 | 0.480 |
Why?
|
| Oncolytic Virotherapy | 3 | 2020 | 42 | 0.460 |
Why?
|
| Bone Neoplasms | 3 | 2020 | 329 | 0.450 |
Why?
|
| Molecular Biology | 4 | 2022 | 89 | 0.450 |
Why?
|
| Genomics | 3 | 2020 | 777 | 0.440 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2013 | 4 | 0.440 |
Why?
|
| Clarithromycin | 1 | 2013 | 7 | 0.440 |
Why?
|
| Anal Canal | 2 | 2013 | 88 | 0.440 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 40 | 0.430 |
Why?
|
| Point Mutation | 2 | 2013 | 245 | 0.430 |
Why?
|
| Bacteriological Techniques | 5 | 2012 | 39 | 0.420 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 37 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 790 | 0.420 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 37 | 0.420 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 395 | 0.420 |
Why?
|
| Nucleic Acids | 1 | 2013 | 32 | 0.420 |
Why?
|
| Gastritis | 1 | 2013 | 36 | 0.420 |
Why?
|
| Endothelial Cells | 2 | 2006 | 462 | 0.410 |
Why?
|
| Stomach | 1 | 2013 | 111 | 0.410 |
Why?
|
| Prostate-Specific Antigen | 4 | 2013 | 360 | 0.380 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 530 | 0.380 |
Why?
|
| Biomarkers, Tumor | 7 | 2024 | 1556 | 0.370 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2021 | 887 | 0.370 |
Why?
|
| Sensitivity and Specificity | 18 | 2019 | 2019 | 0.360 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 6842 | 0.350 |
Why?
|
| Neoplasms | 4 | 2022 | 3081 | 0.340 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2010 | 83 | 0.340 |
Why?
|
| Robotics | 1 | 2013 | 269 | 0.340 |
Why?
|
| Influenza A virus | 1 | 2010 | 169 | 0.340 |
Why?
|
| Staphylococcus | 2 | 2009 | 24 | 0.340 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2009 | 46 | 0.330 |
Why?
|
| Laboratories | 1 | 2009 | 44 | 0.330 |
Why?
|
| Bacteria | 1 | 2013 | 481 | 0.330 |
Why?
|
| CA-19-9 Antigen | 3 | 2015 | 12 | 0.330 |
Why?
|
| Middle Aged | 27 | 2024 | 26089 | 0.320 |
Why?
|
| BRCA2 Protein | 1 | 2009 | 161 | 0.320 |
Why?
|
| Adenoviridae | 2 | 2020 | 349 | 0.310 |
Why?
|
| BRCA1 Protein | 1 | 2009 | 204 | 0.310 |
Why?
|
| Klebsiella pneumoniae | 3 | 2014 | 39 | 0.310 |
Why?
|
| Dysentery | 1 | 2007 | 3 | 0.300 |
Why?
|
| Male | 32 | 2024 | 42588 | 0.290 |
Why?
|
| Oncolytic Viruses | 2 | 2019 | 24 | 0.290 |
Why?
|
| Chlamydophila psittaci | 1 | 2007 | 2 | 0.290 |
Why?
|
| Methicillin Resistance | 4 | 2008 | 32 | 0.290 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2007 | 17 | 0.290 |
Why?
|
| Aged | 21 | 2024 | 19254 | 0.290 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2001 | 195 | 0.290 |
Why?
|
| Eye Neoplasms | 1 | 2007 | 27 | 0.290 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 261 | 0.280 |
Why?
|
| Chlamydia Infections | 1 | 2007 | 31 | 0.280 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 1998 | 58 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 3 | 2014 | 122 | 0.270 |
Why?
|
| United States | 8 | 2022 | 7028 | 0.270 |
Why?
|
| Genetic Testing | 2 | 2019 | 540 | 0.270 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 45 | 0.270 |
Why?
|
| Laparoscopy | 1 | 2013 | 775 | 0.260 |
Why?
|
| Feces | 1 | 2007 | 331 | 0.260 |
Why?
|
| Plasmodium | 1 | 2005 | 10 | 0.250 |
Why?
|
| Clostridium Infections | 1 | 2007 | 125 | 0.250 |
Why?
|
| Malaria | 1 | 2005 | 23 | 0.250 |
Why?
|
| Trophoblasts | 2 | 1997 | 33 | 0.250 |
Why?
|
| Pathology, Clinical | 3 | 2019 | 34 | 0.240 |
Why?
|
| Cell Communication | 1 | 2005 | 200 | 0.230 |
Why?
|
| Adult | 20 | 2024 | 26711 | 0.230 |
Why?
|
| Staphylococcus aureus | 5 | 2008 | 276 | 0.230 |
Why?
|
| Female | 27 | 2024 | 46398 | 0.220 |
Why?
|
| Klebsiella Infections | 3 | 2014 | 30 | 0.220 |
Why?
|
| Gene Amplification | 2 | 2018 | 135 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 164 | 0.220 |
Why?
|
| Microsatellite Repeats | 2 | 2001 | 148 | 0.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2001 | 47 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 3 | 1999 | 30 | 0.210 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 36 | 0.210 |
Why?
|
| Sputum | 2 | 2001 | 35 | 0.200 |
Why?
|
| ErbB Receptors | 2 | 1997 | 501 | 0.200 |
Why?
|
| Accreditation | 1 | 2022 | 62 | 0.200 |
Why?
|
| Paraffin Embedding | 2 | 2013 | 78 | 0.190 |
Why?
|
| Formaldehyde | 2 | 2013 | 52 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 417 | 0.190 |
Why?
|
| Genetics | 1 | 2001 | 24 | 0.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2013 | 78 | 0.190 |
Why?
|
| Outpatients | 1 | 2021 | 100 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2001 | 76 | 0.190 |
Why?
|
| Genetic Vectors | 2 | 2020 | 446 | 0.190 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.190 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2001 | 101 | 0.180 |
Why?
|
| Skin Neoplasms | 5 | 1999 | 583 | 0.180 |
Why?
|
| Blood Banks | 1 | 2020 | 7 | 0.180 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2020 | 9 | 0.180 |
Why?
|
| Blood Donors | 1 | 2020 | 22 | 0.180 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 896 | 0.170 |
Why?
|
| Serial Publications | 1 | 2019 | 2 | 0.170 |
Why?
|
| Laboratory Personnel | 1 | 2019 | 2 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 309 | 0.170 |
Why?
|
| Blood | 3 | 2013 | 69 | 0.170 |
Why?
|
| Donor Selection | 1 | 2020 | 75 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 136 | 0.170 |
Why?
|
| Specimen Handling | 3 | 2013 | 102 | 0.170 |
Why?
|
| Blood Transfusion | 1 | 2020 | 170 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 24 | 0.160 |
Why?
|
| Microbiological Techniques | 3 | 2014 | 24 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1999 | 73 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 64 | 0.160 |
Why?
|
| Immunity | 1 | 2019 | 141 | 0.150 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 983 | 0.150 |
Why?
|
| Prognosis | 2 | 2024 | 3801 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 1989 | 79 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2011 | 681 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2579 | 0.150 |
Why?
|
| RNA, Bacterial | 1 | 1998 | 111 | 0.140 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1997 | 50 | 0.140 |
Why?
|
| Choriocarcinoma | 1 | 1997 | 7 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2013 | 88 | 0.140 |
Why?
|
| Bronchoscopes | 1 | 1996 | 4 | 0.140 |
Why?
|
| Prostate | 3 | 2015 | 393 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1728 | 0.140 |
Why?
|
| Equipment Contamination | 1 | 1996 | 23 | 0.140 |
Why?
|
| Pancreatectomy | 2 | 2014 | 163 | 0.140 |
Why?
|
| Software | 1 | 2020 | 666 | 0.140 |
Why?
|
| Microsomes, Liver | 2 | 1987 | 49 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2014 | 150 | 0.130 |
Why?
|
| Cell Aggregation | 2 | 2006 | 39 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9091 | 0.130 |
Why?
|
| Microarray Analysis | 2 | 2013 | 96 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2014 | 348 | 0.130 |
Why?
|
| Culture Media, Conditioned | 2 | 2006 | 103 | 0.130 |
Why?
|
| Decorin | 1 | 2014 | 6 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.120 |
Why?
|
| Species Specificity | 3 | 2007 | 685 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 287 | 0.120 |
Why?
|
| Protein Array Analysis | 2 | 2011 | 52 | 0.120 |
Why?
|
| Immunoassay | 2 | 2019 | 91 | 0.120 |
Why?
|
| Child | 4 | 2020 | 7202 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 826 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2018 | 1100 | 0.120 |
Why?
|
| Pancreatitis, Chronic | 2 | 2015 | 54 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2642 | 0.110 |
Why?
|
| Adolescent | 5 | 2020 | 9290 | 0.110 |
Why?
|
| Young Adult | 4 | 2020 | 6350 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 46 | 0.110 |
Why?
|
| Placental Hormones | 1 | 1993 | 3 | 0.110 |
Why?
|
| Fixatives | 1 | 2013 | 12 | 0.110 |
Why?
|
| Gram-Positive Bacteria | 1 | 2013 | 18 | 0.110 |
Why?
|
| Epidemiological Monitoring | 1 | 2013 | 39 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 1999 | 1226 | 0.110 |
Why?
|
| Electrophoresis | 1 | 2013 | 55 | 0.110 |
Why?
|
| Genes, Bacterial | 1 | 2014 | 198 | 0.110 |
Why?
|
| Tissue Fixation | 1 | 2013 | 40 | 0.110 |
Why?
|
| Kallikreins | 1 | 2013 | 49 | 0.110 |
Why?
|
| Base Sequence | 2 | 2007 | 2331 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2015 | 213 | 0.110 |
Why?
|
| Long-Term Care | 1 | 2013 | 61 | 0.110 |
Why?
|
| Cryopreservation | 1 | 2013 | 70 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2014 | 161 | 0.110 |
Why?
|
| Cladribine | 1 | 1992 | 35 | 0.110 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1992 | 186 | 0.100 |
Why?
|
| Culture Media | 1 | 2012 | 147 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 269 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2012 | 262 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1246 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 761 | 0.100 |
Why?
|
| Mucins | 1 | 2011 | 39 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2015 | 1864 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2001 | 4311 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2005 | 250 | 0.090 |
Why?
|
| Escherichia coli | 1 | 2014 | 606 | 0.090 |
Why?
|
| Nose | 3 | 2008 | 94 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2012 | 203 | 0.090 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2010 | 5 | 0.090 |
Why?
|
| Risk Management | 1 | 2010 | 43 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 9 | 0.090 |
Why?
|
| Skin Diseases | 1 | 2012 | 173 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cross Infection | 2 | 2010 | 149 | 0.090 |
Why?
|
| Cell Division | 2 | 2005 | 696 | 0.090 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 15 | 0.090 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 1720 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 172 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 156 | 0.080 |
Why?
|
| Biopsy | 1 | 2013 | 1185 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 864 | 0.080 |
Why?
|
| Genome, Human | 1 | 2014 | 792 | 0.080 |
Why?
|
| Lectins | 1 | 2009 | 84 | 0.080 |
Why?
|
| Pyridines | 2 | 1989 | 316 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2009 | 161 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1802 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 156 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2009 | 90 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2009 | 192 | 0.080 |
Why?
|
| Antibodies | 2 | 2009 | 354 | 0.080 |
Why?
|
| Vancomycin Resistance | 1 | 2008 | 18 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 482 | 0.080 |
Why?
|
| DNA | 3 | 2010 | 1309 | 0.080 |
Why?
|
| Enterococcus | 1 | 2008 | 35 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 234 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 856 | 0.070 |
Why?
|
| Animals | 9 | 2020 | 27448 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 868 | 0.070 |
Why?
|
| Cell Movement | 2 | 2014 | 785 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2007 | 173 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2009 | 335 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2020 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 114 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2010 | 351 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 1058 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2008 | 216 | 0.070 |
Why?
|
| Cell Line | 2 | 2009 | 2496 | 0.070 |
Why?
|
| Gene Transfer Techniques | 2 | 2019 | 153 | 0.070 |
Why?
|
| Interferon-alpha | 3 | 1993 | 226 | 0.070 |
Why?
|
| Jews | 1 | 2006 | 42 | 0.070 |
Why?
|
| Genes, APC | 1 | 2006 | 27 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 1997 | 306 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 3017 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2020 | 818 | 0.060 |
Why?
|
| Chemotactic Factors | 1 | 2005 | 14 | 0.060 |
Why?
|
| Transition Temperature | 1 | 2005 | 11 | 0.060 |
Why?
|
| DNA, Protozoan | 1 | 2005 | 16 | 0.060 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2005 | 34 | 0.060 |
Why?
|
| DNA Probes | 1 | 2005 | 77 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2005 | 175 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2019 | 3398 | 0.060 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 96 | 0.060 |
Why?
|
| Bacteremia | 1 | 2005 | 102 | 0.060 |
Why?
|
| Cell Biology | 1 | 2004 | 15 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1997 | 374 | 0.060 |
Why?
|
| Thermodynamics | 1 | 2005 | 313 | 0.060 |
Why?
|
| Imidazoles | 1 | 1984 | 148 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2024 | 54 | 0.060 |
Why?
|
| Collagen | 1 | 2005 | 294 | 0.060 |
Why?
|
| Patient Admission | 2 | 2008 | 114 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2004 | 156 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 364 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2019 | 3748 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3027 | 0.050 |
Why?
|
| Chemistry, Clinical | 1 | 2001 | 2 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 75 | 0.050 |
Why?
|
| Societies, Scientific | 1 | 2001 | 43 | 0.050 |
Why?
|
| Mucin 5AC | 2 | 2011 | 8 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2004 | 262 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2000 | 27 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 131 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2378 | 0.040 |
Why?
|
| Time Factors | 3 | 2012 | 5344 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2006 | 797 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 1999 | 3671 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 58 | 0.040 |
Why?
|
| Chromogenic Compounds | 2 | 2012 | 5 | 0.040 |
Why?
|
| Mice | 3 | 2020 | 11809 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 140 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 160 | 0.040 |
Why?
|
| Clone Cells | 1 | 1999 | 214 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2765 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 3168 | 0.040 |
Why?
|
| Enzyme Induction | 3 | 1989 | 88 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 1999 | 183 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1442 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 173 | 0.040 |
Why?
|
| Virus Replication | 1 | 2019 | 326 | 0.040 |
Why?
|
| Pregnancy | 2 | 1997 | 3026 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1998 | 150 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 188 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 276 | 0.040 |
Why?
|
| PUVA Therapy | 3 | 1993 | 24 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 22 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 202 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 443 | 0.030 |
Why?
|
| Chicago | 2 | 2012 | 1432 | 0.030 |
Why?
|
| Sterilization | 1 | 1996 | 8 | 0.030 |
Why?
|
| Dimethylnitrosamine | 2 | 1987 | 4 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1601 | 0.030 |
Why?
|
| RNA | 2 | 1997 | 581 | 0.030 |
Why?
|
| Mycosis Fungoides | 2 | 1993 | 29 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 1997 | 2023 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 223 | 0.030 |
Why?
|
| Neoplasm Seeding | 1 | 1996 | 16 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 424 | 0.030 |
Why?
|
| Ethanol | 2 | 1989 | 252 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1997 | 162 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 1993 | 217 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 1996 | 189 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 2568 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 480 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 805 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1997 | 395 | 0.030 |
Why?
|
| Rabbits | 2 | 1987 | 639 | 0.030 |
Why?
|
| Gene Expression | 1 | 1999 | 1310 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 1987 | 388 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Medical Overuse | 1 | 2015 | 36 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 33 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 80 | 0.030 |
Why?
|
| Cefotaxime | 1 | 2014 | 5 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2014 | 9 | 0.030 |
Why?
|
| Singapore | 1 | 2014 | 16 | 0.030 |
Why?
|
| Ceftazidime | 1 | 2014 | 8 | 0.030 |
Why?
|
| Gentamicins | 1 | 2014 | 20 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1993 | 20 | 0.030 |
Why?
|
| Mass Screening | 2 | 2012 | 641 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2014 | 35 | 0.030 |
Why?
|
| Logistic Models | 1 | 1997 | 1215 | 0.030 |
Why?
|
| Phenazines | 1 | 2013 | 7 | 0.030 |
Why?
|
| Gentian Violet | 1 | 2013 | 10 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 605 | 0.030 |
Why?
|
| Culture Media, Serum-Free | 1 | 1993 | 22 | 0.030 |
Why?
|
| Thymidine | 1 | 1993 | 59 | 0.030 |
Why?
|
| China | 1 | 2014 | 235 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 374 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 1993 | 63 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1993 | 70 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1993 | 251 | 0.030 |
Why?
|
| Lymphoma, T-Cell | 1 | 1993 | 55 | 0.030 |
Why?
|
| Platelet Count | 1 | 1992 | 93 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 900 | 0.030 |
Why?
|
| Agar | 1 | 2012 | 8 | 0.030 |
Why?
|
| Chickenpox | 1 | 2012 | 38 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1992 | 223 | 0.030 |
Why?
|
| Mitochondria | 1 | 1996 | 553 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 40 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2013 | 478 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 780 | 0.030 |
Why?
|
| CA-125 Antigen | 1 | 2011 | 22 | 0.030 |
Why?
|
| Herpes Zoster | 1 | 2012 | 79 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1992 | 192 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 988 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1993 | 187 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 435 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 565 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 177 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2010 | 2487 | 0.020 |
Why?
|
| Simplexvirus | 1 | 2012 | 151 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 148 | 0.020 |
Why?
|
| Multi-Institutional Systems | 1 | 2010 | 4 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1535 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1992 | 445 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2011 | 86 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 859 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2012 | 159 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 417 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 194 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2010 | 26 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2010 | 17 | 0.020 |
Why?
|
| Triage | 1 | 2010 | 113 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2009 | 50 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 230 | 0.020 |
Why?
|
| Forecasting | 1 | 2010 | 306 | 0.020 |
Why?
|
| Hospitals | 1 | 2012 | 302 | 0.020 |
Why?
|
| Carbohydrate Conformation | 1 | 2009 | 18 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 294 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 1989 | 17 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1116 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1990 | 186 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2009 | 318 | 0.020 |
Why?
|
| Chlorhexidine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mupirocin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 503 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 337 | 0.020 |
Why?
|
| Disinfectants | 1 | 2008 | 8 | 0.020 |
Why?
|
| Universal Precautions | 1 | 2008 | 5 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2008 | 50 | 0.020 |
Why?
|
| Hexobarbital | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1987 | 9 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 880 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2880 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1993 | 2884 | 0.020 |
Why?
|
| NADP | 1 | 1987 | 45 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 312 | 0.020 |
Why?
|
| Carrier State | 1 | 2007 | 39 | 0.020 |
Why?
|
| Infection Control | 1 | 2008 | 122 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2006 | 60 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1577 | 0.020 |
Why?
|
| Cecal Neoplasms | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sigmoid Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
|
| Trisomy | 1 | 2006 | 54 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 97 | 0.020 |
Why?
|
| Leucovorin | 1 | 2006 | 224 | 0.020 |
Why?
|
| Omentum | 1 | 2006 | 74 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2003 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 231 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2010 | 659 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 1993 | 1012 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 1490 | 0.020 |
Why?
|
| Anisoles | 1 | 1984 | 5 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 1984 | 5 | 0.020 |
Why?
|
| Alcohols | 1 | 1984 | 15 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1226 | 0.020 |
Why?
|
| Chemistry | 1 | 1984 | 54 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1984 | 72 | 0.020 |
Why?
|
| Monoamine Oxidase | 1 | 1984 | 25 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1984 | 38 | 0.020 |
Why?
|
| Kinetics | 1 | 1987 | 1534 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 1984 | 44 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2006 | 289 | 0.010 |
Why?
|
| Biomarkers | 1 | 2011 | 1771 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1280 | 0.010 |
Why?
|
| Aniline Compounds | 1 | 1984 | 59 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2008 | 396 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2006 | 184 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2006 | 560 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 71 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1984 | 352 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2450 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 313 | 0.010 |
Why?
|
| Sleep | 1 | 1987 | 454 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 3229 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 996 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 200 | 0.010 |
Why?
|
| Rats | 1 | 1987 | 4044 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 297 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 138 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 972 | 0.010 |
Why?
|
| Hematology | 1 | 2000 | 30 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 2000 | 52 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1412 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 767 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2000 | 63 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 2368 | 0.010 |
Why?
|
| MERRF Syndrome | 1 | 1996 | 2 | 0.010 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 1996 | 5 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2000 | 579 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1996 | 73 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2000 | 384 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1996 | 83 | 0.010 |
Why?
|
| Epithelium | 1 | 1996 | 325 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1993 | 67 | 0.010 |
Why?
|
| Antigens, CD7 | 1 | 1993 | 2 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1993 | 14 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 1993 | 24 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1993 | 64 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 97 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1993 | 134 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1993 | 466 | 0.010 |
Why?
|
| Remission Induction | 1 | 1993 | 741 | 0.010 |
Why?
|
| Sezary Syndrome | 1 | 1990 | 12 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1993 | 600 | 0.010 |
Why?
|
| Skin | 1 | 1993 | 585 | 0.010 |
Why?
|
| Nitrogen | 1 | 1989 | 73 | 0.000 |
Why?
|